ABSTRACT
The aim of this prospective, randomized, and double-blinded study was to compare the effects of desflurane, sevoflurane, propofol on both atrial and ventricular wall function by measurement of QT dispersion (QTd), corrected QT dispersion (QTcd), and P dispersion (Pd) on electrocardiogram (ECG). Forty-six patients from the American Society of Anesthesiologists class I−II undergoing noncardiac surgery, were enrolled in this study. Patients were randomly allocated to receive desflurane, sevoflurane or propofol anesthesia. ECG recordings were taken before and after 5 minutes of drug administration. Induction with desflurane significantly increased the QTd compared to baseline (38 ± 2 ms vs. 62 ± 6 ms, P < 0.05). Sevoflurane and propofol anesthesia was not associated with any changes in QTd. QTcd was increased with desflurane induction and decreased with sevoflurane and propofol induction, but this decrease was only significant in the propofol group (67 ± 5 ms vs. 45 ± 3 ms, P < 0.05). Pd was significantly increased after induction with desflurane (34 ± 3 vs. 63 ± 6 ms, P < 0.05). There was a significant increase in QTd and Pd in desflurane group, but this increment did not cause any dangerous arrhythmias. QTcd significantly decreased in propofol group. We believe that further investigations are required for using desflurane as safe as sevoflurane and propofol in noncardiac surgery patients who have high cardiac arrhythmia and ischemia risk.
Subject(s)
Adult , Anesthetics, Inhalation/adverse effects , Anesthetics, Intravenous/adverse effects , Blood Pressure/drug effects , Double-Blind Method , Electrocardiography/drug effects , Female , Heart Rate/drug effects , Humans , Isoflurane/adverse effects , Isoflurane/analogs & derivatives , Male , Methyl Ethers/adverse effects , Middle Aged , Propofol/adverse effects , Prospective Studies , Surgical Procedures, Operative , Young AdultABSTRACT
Objective To analyze P wave dispersion (Pd) and QT dispersion (QTd) of the patients with cononary heart disease (CHD) before and after percutaneous coronary intervention (PCI) and to evaluate the influence of Tongguan capsule on improving myocardial ischemia in vivo cardiac electrophysiology. Methods 60 CHD patients treated by PCI were divided into the trial group (Tongguan Capsule 4 weeks+ conventional western medicine) and control group (conventional western medicine) randomly. Pd and QTd/QTcd of two groups before and after treamtment were measured. Results Pd and QTd/QTcd of the trial group were obviously declined. The difference between two groups was marked. Conclusion The treatment of Tongguan Capsule can improve Pd and QTd/QTcd of the patients with CHD, which suggest Tongguan Capsule can improve myocardial ischemia.